Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | TYR | P14679 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502575 | 1.00 | PAM (0.70) | PAMAKR1B10AKR1B1CA12CA7 | |
| SCHEMBL11042697 | 0.85 | AKR1B10 (0.55) | PAMAKR1B10AKR1B1CA12CA7 | |
| SCHEMBL2148302 | 0.83 | PAM (1.00) | PAMHCAR2MAOBF3CYP2D6 | |
| SCHEMBL156767 | 0.83 | PAM (1.00) | PAMHCAR2MAOBF3CYP2D6 | |
| SCHEMBL582727 | 0.83 | PAM (1.00) | PAMHCAR2MAOBF3CYP2D6 | |
| SCHEMBL25241811 | 0.82 | PAM (0.68) | PAMESR1ESR2MAOBCYP2D6 | |
| SCHEMBL9044093 | 0.82 | PAM (0.68) | PAMCA1MAOBCYP3A4RAB9A | |
| SCHEMBL9161835 | 0.82 | PAM (0.68) | PAMMAOBCYP2D6CYP3A4NFKB1 | |
| SCHEMBL9046738 | 0.82 | PAM (0.68) | PAMMAOBALDH1A1MAPT | |
| SCHEMBL9161849 | 0.82 | PAM (0.68) | PAMMAOBCYP2D6CYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510397-A | Styrene acetate compound and preparation method and application thereof | 青海大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20220211796-A1 | PEPTIDE ANTIBIOTICS AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2020232407-A9 | PEPTIDE ANTIBIOTICS AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020232407-A1 | PEPTIDE ANTIBIOTICS AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2020-11-19 | — | — | WO | disclosed |
| US-7923578-B2 | Prevent sagging of skin; luster ; amidation of 3-(4-hydroxyphenyl)propionic acid with ammonia using 4-nitrophenol in ethyl acetateand dicyclohexylcarbodiimide; stirring ; precipitation dicyclohexylurea; filtration under vacuum | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2011-04-12 | — | — | US | disclosed |
| US-20090191118-A1 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 | ARIUS RESEARCH INC. | 2009-07-30 | — | — | US | disclosed |
| EP-1841795-A4 | CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 | ARIUS RES INC (CA) | 2009-05-06 | — | — | EP | disclosed |
| US-20090053215-A1 | Cytotoxicity mediation of cells evidencing surface expression of CD63 | ARIUS RESEARCH INC. (CA) | 2009-02-26 | — | — | US | disclosed |
| EP-1996700-A1 | CANCEROUS DISEASE MODIFYING ANTIBODY 141205-05 | Arius Research Inc. (CA) | 2008-12-03 | — | — | EP | disclosed |
| US-20080249334-A1 | Method of Manufacturing 3-(4-Hydroxyphenyl)Propanoic Acid Amide, Its Application in the Manufacture of Anti-Aging Compositions and Anti-Aging Composition | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2008-10-09 | — | — | US | disclosed |
| WO-2007095748-A1 | CANCEROUS DISEASE MODIFYING ANTIBODY 141205-05 | ARIUS RESEARCH INC. (CA) | 2007-08-30 | — | — | WO | disclosed |
| US-20070202113-A1 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 | ARIUS RESEARCH, INC. | 2007-08-30 | — | — | US | disclosed |
| CN-1960756-A | Cell-mediated cytotoxicity (CD 63) demonstration of cell membrane surface expression | ARIUS RES INC (CA) | 2007-05-09 | — | — | CN | disclosed |
| WO-2007046721-A2 | A METHOD OF MANUFACTURING 3-(4-HYDROXYPHENYL)PROPANOIC ACID AMIDE, ITS APPLICATION IN THE MANUFACTURE OF ANTI-AGING COMPOSITIONS AND AN ANTI-AGING COMPOSITION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2007-04-26 | — | — | WO | disclosed |
| WO-2005092377-A9 | CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 | ARIUS RES INC (CA) | 2007-03-22 | — | — | WO | disclosed |
| EP-1732603-A1 | CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 | Arius Research, Inc. (CA) | 2006-12-20 | — | — | EP | disclosed |
| US-20060204497-A1 | Cytotoxicity mediation of cells evidencing surface expression of CD63 | ARIUS RESEARCH INC (CA) | 2006-09-14 | — | — | US | disclosed |
| WO-2006072166-A1 | CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 | ARIUS RESEARCH, INC. (CA) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005092377-A1 | CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 | ARIUS RESEARCH, INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| US-20040258693-A1 | Cytotoxicity mediation of cells evidencing surface expression of CD63 | HOFFMAN-LA ROCHE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211796-A1 | PEPTIDE ANTIBIOTICS AND METHODS OF USE THEREOF | VIP, NGLY1, PEPD | PAM 80/4885AKR1B10 4379/4885AKR1B1 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.